Despite the encouraging results of GLP-1/glucagon co-agonism in experimental models, different GLP-1 and glucagon co-agonists have shown various levels of efficacy and tolerability in people with obesity and/or T2D, in early phase clinical trials, which may be explained by the different ratio of GLP-1 to glucagon activity between the different molecules [65]
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial
A 2022 analysis of the SUSTAIN and STEP trial data published in Obesity Reviews found a clear and consistent relationship between dose escalation speed and gastrointestinal side effect severity
As our knowledge of GLP-1 biology advances and novel therapeutic innovations arise, these agents are expected to assume a progressively pivotal role in the management of metabolic disorders and their related complications, ultimately enhancing patient outcomes across various disease states
Our program focuses on medically appropriate GLP-1 prescriptions based on clinical evaluation not automatic dose escalation
According to Truveta Research presented at ISPOR 2025, side effects were the leading reason patients stopped taking GLP-1 medications, accounting for 28.2% of all discontinuations
![what are the qualifications for semaglutide How to File an Ozempic Lawsuit [2026 Update] What are the eligibility criteria –](https://www.robertkinglawfirm.com/wp-content/uploads/2024/08/ozempic-lawsuit-eligibility-qualifications.webp)
